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Summary
Background. — Progress in therapy and the ageing patients hospitalized with heart failure may
have impacted the characteristics of this patients.
Aims. — We compared epidemiological data of patients admitted with heart failure during two
periods separated by a 10 year interval. 
Methods. — Characteristics of 353 heart failure patients recruited between 2002 and 2004
with those of 304 heart failure patients recruited between 1992 and 1994 were compared
retrospectively. 
Results. — There is now a majority of male patients (56.4%) not found ten years ago. The
average age is unchanged (75.1±11 then 76.4±11 years) even though the proportion of patients
aged over 70 years has increased (75% versus 70%). Hospital length of stay has fallen from 14±9
to 10±7 days. Hospital mortality (8%) are identical. The two main etiologies remain coronary
and hypertensive heart disease at 29 and 24% respectively but these proportions are lower than
ten years ago (42 and 28% respectively). The ejection fraction is more often preserved (56%)
than before (44%). Increased prescription of inhibitors of the renin-angiotensin system and
beta-blockers is confirmed. Post-hospital and total mortality has fallen by 50 and 30% from 30
to 16% and 35 to 24% respectively at the expense of a 25% increase in the frequency of hospital
readmissions from 29 to 38%.
Conclusion. — Even if mortality has declined, heart failure remains a major public health burden
with a significant number of hospital readmissions. Other approaches such as therapeutic education
must therefore be developed.
© 2008 Published by Elsevier Masson SAS.
Résumé
Justification. — Les progrès thérapeutiques et le vieillessement des patients hospitalisés pour
insuffisnace cardiaque doivent avoir un impact sur les caractéristiques de ces patients. 
Objectifs. — Nous avons comparé les données épidémiologiques de patients hospitalisés pour
insuffisance cardiaque durant deux périodes espacées de dix ans.
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Méthodes. — Les caractéristiques de 353 patients insuffisants cardiaques recrutés entre 2002
et 2004 à celles de 304 patients insuffisants cardiaques recrutés entre 1992 et 1994 ont été
comparées rétrospectivement.
Résultats. — Une majorité masculine (56.4%), qui n'existait pas dix ans plutôt, est apparue.
L'âge moyen n'a pas évolué (75.1±11 puis 76.4±11 ans) même si la proportion de patients de plus
de 70 ans a augmenté (75% contre 70 %). La durée d'hospitalisation est passée de 14±9 à
10±7 jours. La mortalité hospitalière(8%) est identique. Les deux étiologies principales restent
les coronaropathies et l'hypertension artérielle avec respectivement 29 et 24% mais dans des
proportions moindres que dix ans auparavant (respectivement 42 et 28%). La fraction d'éjection
est plus souvent préservée (56%) qu'avant (44%). L'augmentation de prescription d'inhibiteurs
du système rénine-angiotensine et de bétabloquants est confirmée. Les mortalités post-
hospitalière et totale ont baissé de 50 et 30% passant respectivement de 30 à 16% et de 35 à
24% au prix d'une augmentation du nombre de ré-hospitalisations de 25%, passant de 29 à 38%.
Conclusion. — Même si la mortalité baisse, l'insuffisance cardiaque reste un enjeu de santé
publique avec un nombre de ré-hospitalisations important qui doit faire explorer d'autres pistes
comme l'éducation thérapeutique.
© 2008 Published by Elsevier Masson SAS.
Heart failure (HF) remains a frequent reason for admission
and readmission to hospital and therefore represents a
major public health burden [1,2]. The ageing of the popula-
tion and changes in HF management have impacted the
characteristics of patients suffering from this disorder. We
report here a comparative study in the same General Hospi-
tal center (CHG) on two cohorts at ten year intervals.
Materials and methods
The objective of our retrospective study was to compare
epidemiological data for patients admitted with HF as main
diagnosis (PMSI code) in the same GHC cardiology depart-
ment during two periods separated by a 10 year interval:
between January 1, 1992 and December 31, 1994 (Period 1)
with an mea of 30 months follow-up on the one hand and
between January 1, 2002 and December 31, 2004 (Period 2)
on the other, with the same mean duration of follow-up.
Patients admitted to hospital for acute coronary syndrome,
patients in whom coronary artery or heart valve surgery was
indicated and those who received multisite stimulation
(therapy not available during period 1) were excluded. The
diagnosis of HF was made from an analysis of clinical and
radiological findings and the response to diuretic treatment
according to guidelines [3] Serum creatinine levels confir-
med the diagnosis of severe renal insufficiency when this
parameter was higher than 250 micrograms per liter, either
on admission or during hospitalization. The proportion of
patients who received transthoracic Doppler echocardio-
graphy (TTE) was very high: 92% and the same for both
periods so that only these patients were selected. This
investigation contributed to the etiological assessment
complementing the existence of a history of myocardial
infarction, hypertension and severe heart valve disease.
The diagnosis of hypertrophic cardiomyopathy if left ventri-
cular hypertrophy (interventricular septum ≥ 13 mm) was
observed outside high blood pressure and dilated cardio-
myopathy when the left ventricle was dilated (end-diastolic
diameter greater than 55 mm) after excluding other causes.
In addition, this investigation made it possible to distinguish
heart failure with preserved left ventricular systolic func-
tion (HF-PSF) when the ejection fraction (EF) was ≥50% and
heart failure with impaired systolic function (HF-ISF) when
it was <50%. Finally, the systolic pulmonary artery pressure
(SPAP) was evaluated (normal value lower than 45mmHg).
Discharge medication was systematically noted. Patient fol-
low-up was conducted by telephone to study mortality and
hospital readmissions. Quantitative variables are described
using means, standard deviations and minimal and maxi-
mum values. Qualitative variables are expressed as sample
sizes and percentages. Student’s t-test and Chi-square tests
were used for comparative analysis.
Results
During period 1 (1992-1994), 330 patients, including 304
who underwent transthoracic echocardiography, were hos-
pitalized for HF out of 1.725 admissions to the cardiology
department, i.e. 19.1% of admitted patients (330/1725).
For period 2 (2002-2004), this proportion was 19.4% i.e.
383/1976 (with 353 investigated by TTE): the difference
was not statistically significant. Clinical, electrocardiogra-
phy and echocardiography data are given in table 1. The sex
distribution differed in the two periods: There was a signi-
ficant male majority for the current period with 56.4% of
men (p<0.001) whereas, ten years ago, no difference
between the sexes was observed (53.6% men with p = ns).
The current mean age of patients is 76.4±11.4 years (range:
19-99 years) and was 75.1 ± 11.2 years (range: 35-97 years)
ten years earlier (p = ns) even if 70% (214/304) of the
patients were over 70 years versus 75% (265/353) now
(p=ns). Currently, patients hospitalized for HF are mainly
(218/353) in NYHA class III (62%) whereas ten years earlier,
they were mainly (196/304) in NYHA class IV (65%). The dia-
gnosis of global HF was made in 56.6% (200/353) of cases for
period 2 versus only 37% (113/304) ten years earlier
(p<0.001). Rhythm disorders were observed in 49.6% (175/
353) of patients for period 2 whereas they were recorded in
82% (249/304) of cases during period 1 (p<0.001). Atrial
fibrillation (AF) remained the most frequent arrhythmia
and was observed in 36.8% (130/353) of hospitalized
patients: this rate was similar ten years before (107/304
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i.e. 35.2%). Other rhythm disorders, represented by other
supraventricular tachycardias and atrial and ventricular
extrasystoles were more frequently observed during the
first period (46.6% versus 12.5% now). The presence of a
complete left bundle branch block was stable (52/304 i.e.
17.1% for period 1 versus 48/353 or 13.6% for period 2). This
was more often observed (p < 0.05) in patients with a fall in
the ejection fraction (21% on average for the 2 periods)
whereas it was only observed in a mean of 9% of those
with a preserved ejection fraction. Sixty-eight percent of
patients (241/353) had a concomitant chronic disease such
as diabetes, chronic respiratory insufficiency, chronic renal
failure or dysthyroidism. Diabetes was the most frequent
concomitant disease though the proportion has not changed
in ten years (28 and 28.6%). A main predisposing factor for
acute HF was demonstrated in 68.8% of cases (243/353)
whereas it was previously found in 80.6% (245/304)
p<0.001): bronchopulmonary infections and arrhythmias
were the most often involved. In ten years, the proportion
of HF-PSF has been reversed: it was previously observed in
44,4% patients whereas currently, it predominates at 55.8%
(p < 0.001). Left ventricular hypertrophy (LVH) was detec-
ted in 151 patients or 39.4% (139/353) of cases in the recent
group versus 30.3% of patients 10 years ago (92/304)
showing a significant increase (p<0.05). The proportion of
patients with pulmonary arterial hypertension (PAH) is
identical in the 2 periods: 20.1% (61/304) during period 1
and 21.2% (75/353) during period 2. The etiologies of HF are
listed in table 2. Currently, ischemic (28.9%) and hyperten-
sive heart disease (24%) remain the two most frequent etio-
logies but in statistically smaller proportions than ten years
earlier (42.4 and 27.6% respectively). On the other hand,
there has been a significant increase in the proportion of
dilated cardiomyopathies from 12.2 to 19.3%. It should be
noted that the proportion of other types of heart disease
(such as cor pulmonale, congenital and toxic heart disease)
and heart disease of undetermined cause increased signifi-
cantly from 5.2 to 18.4%. Among these; the proportion of
HF-PSF was statistically greater (table 2). The hospital out-
come is reported in table 3. For period 2, the mean length
of stay (LOS) was 10±7 days (range between 1 and 51 days)
whereas over period 1, it was 14 ± 9 days (range from 1 to
44): the difference is significant (p < 0.001). Complications
during the hospital phase remained frequent: they occurred
in 135 of the 353 patients (38.2%) during period 2 and in 124
of the 304 patients (41.7%) during period 1 (p=ns). For
period 2, death occurred in 8.5% of cases (30/353), renal
insufficiency in 10.7% of cases (38/353) and a rhythm or
conduction disorder in 4.8% of cases (17/353). Ten years
earlier, death (7.6% or 23/304) and renal insufficiency were
as frequent (10.5%: 32/304) (p<0.001) but rhythm or con-
duction disorders occurred significantly more often (13.1%
or 40/304). Discharge medication is specified in table 4.
Although there was a fall in the prescription of digitalis pre-
Table 1 Changes in clinical and paraclinical characteristics.
2002-2004 1992-1994 p
Number of patients n = 353 n = 304
Age (years) 76.4 ± 11.4 75.1 ± 11.2 ns
Male sex % (n) 56.4 (199) 53.6 (163) ns
Female sex % (n) 43.6 (154) 46.4 (141) ns
NYHA III % (n) 62 (218) 25 (77) < 0.001
NYHA IV % (n) 23 (80) 64 (196) < 0.001
Global heart failure % (n) 56.6 (200) 37 (113) < 0.001
Rhythm disorders % (n) 49.6(175) 82(249) < 0.001
– Atrial fibrillation % (n) 36.8 (130) 35.2 (107) ns
– Others (SVT excluding FA, VES, AES) 12.5 (45) 46.6 (142) < 0.001
Left BBB % (n) 13.6 (48) 17.1 (52) ns
HF-PSF % (n) 55.8 (197) 44.4 (135) < 0.01
HF-ISF % (n) 44.2 (156) 55.6 (169) < 0.01
LVH % (n) 39.4 (139) 30.2 (92) < 0.05
LV Dilatation % (n) 41.7 (160) 48 (146) < 0.01
PAH % (n) 21.2 (75) 20.1 (61) ns
Associated diseases % (n) 68.3 (241) 71 (216) ns
– Diabetes % (n) 28 (100) 28.6 (87) ns
– Respiratory insufficiency % (n) 18.1 (65) 18.1 (65) ns
– Chronic kidney failure % (n) 8.8 (31) 11.6 (36) ns
– Thyroid dysfunction % (n) 13 (46) 6.6 (20) < 0.01
Triggering factors % (n) 68.8 (242) 80.6(245) < 0.001
– Acute respiratory infections % (n) 19.3 (68) 25.4 (77) ns
– Acute rhythm disorders % (n) 19.3 (68) 16.5 (50) ns
– Hypertensive flare-up % (n) 11.9 (42) 14.8 (45) ns
– Inadvertent treatment withdrawal % (n) 5.7 (20) 5.6 (17) ns
– Acknowledged deviation from diet % (n) 5.7 (20) 4.3 (13) ns
– Iatrogenic causes* % (n) 3.7 (13) 9.2 (28) < 0.01
*Excessive water and salt infusion, administration of corticosteroids, negative inotropic treatment.
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parations, calcium channel blockers and nitrates, the pres-
cription of inhibitors of the renin-angiotensin system and
especially that of beta-blockers significantly increased. Post-
hospital follow-up concerned 266 patients (15 lost to follow-
up and 23 hospital deaths were excluded) over period 1 with
a mean follow-up duration of 30 ± 17 months (range: 24-48)
and 284 patients (39 lost to follow-up and 30 hospital deaths)
over period 2 with a mean duration of 30 ± 16 months
(range:12-36) (table 5): Post-hospital mortality clearly fell in
ten years passing from 30 to 16.5% (p < 0.001) and total mor-
tality (hospital and post-hospital), also significantly
decreased by 31%, from 35.6% (103/289) to 24.5% (77/314).
This gain only significantly concerned patients with HF-ISF
(table 6). For the period 2 cohort, 38% of patients (108/284)
were readmitted to hospital for HF at least once, compared
to a value of 28.6% of patients (76/266) over period 1 (signi-
ficant increase of 25%). This increase mainly involved
(p < 0.05) patients with HF-ISF (table 5).
Table 2 Changes in etiologies of heart failure.
2002-2004 1992-1994 p
Number of patients n = 353 n = 304
History of MI* % (n) 28.9 (102) 42.4 (129) < 0.001
History of HT** % (n) 24 (85) 27.6 (84) < 0.05
Dilated cardiomyopathy % (n) 19.3 (68) 12.2 (37) < 0.05
Severe valve diseases % (n) 6.2 (22) 9.2 (28) ns
Hypertrophic Cardiomyo. % (n) 3.2 (11) 3.4 (10) ns
Other heart diseases and*** % (n) 
heart disease of undetermined cause
18.2 (65) 5.2 (15) < 0.001
With HF-PSF % (n) 15.3 (54) 2.6(8) < 0.001
With HF-ISF % (n) 3.1 (11) 2.3(7) ns
*Myocardial infarction. **Hypertension.
***Cor pulmonale, congenital cardiopathy, toxic cardiopathy and heart disease of undetermined cause.
Table 3 Hospital outcome.
2002-2004 1992-1994 p
Number of patients n = 353 n = 304
Length of hospital stay (days) 10 ± 7 14 ± 9 < 0.001 
Total complications % (n) 38.2 (135) 41.7 (127) ns
Hospital mortality % (n) 8.5 (30) 7.6 (23) ns
Renal failure % (n) 10.7 (38) 10.5 (32) ns
Ryth. and cond. disorders % (n) 4.8 (17) 13.1 (40) < 0.001
Others* % (n) 13.3 (47) 9.5 (32) ns
*Cardiovascular collapse, hepatic insufficiency, hyponatraemia, arterial or venous thromboembolic accidents.
Table 4 Changes in discharge medication.
2002-2004 1992-1994 p
Number of patients n = 323 n = 281
Diuretics % (n) 92.6 (299) 94.3 (265) ns
ACEi or AIIRA % (n) 73.4 (237) 65.8 (185) < 0.05
Amiodarone % (n) 43 (139) 6.3 (102) ns
Platelet aggregation inhibitors % (n) 42.7 (138) 39.1 (110) ns
Vitamin K antagonists % (n) 37.9 (122) 13.9 (39) < 0.001
Calcium antagonists % (n) 8 (26) 19.2 (54) < 0.001
Digoxin % (n) 15.8 (51) 36.3 (102) < 0.001
Betablockers % (n) 13.6 (44) 7.1 (20) < 0.01
Nitrates % (n) 11.5 (37) 55.5 (156) < 0.001
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Discussion
There are few data in the literature about HF in the
French population. Beside registries and surveys, we thought
it interesting to analyze the epidemiologic data for this
disorder at an interval of ten years in the same hospital cen-
ter. Even if the number of hospitalizations in this department
has increased by 14.5%, from 1.725 to 1.976, there was no
statistical difference in the proportion of patients admitted
for HF between the two periods (17.6% versus 19.4%). In
2005, data obtained in the “sentinel” network [4] on the pre-
valence and management of HF in subjects aged 60 years or
more seen by GPs were published: The prevalence increased
with age and exceeded 20% from 80 years. Likewise, most
hospitalized patients were aged over 75 years [5]. In our
series, the proportion of patients aged over 70 years
increased from 70 to 75% although there was no significant
increase in the average age. Cohen-Solal [6] in 1997, on a
multicentre series concerning 1.058 patients admitted to
hospital for HF over 1 month and, Dujardin [7], in 1999-2000,
on 1.772 patients in several cardiology departments over two
close periods reported similar epidemiological data to ours
for the most recent period. Moreover, our study revealed
that these data have not changed for ten years. On the other
hand, the proportion of HF-PSF in the series of Dujardin,
using the same EF cut-off of 50%, is lower (30%) than in our
series (55.8%). This difference may partly be explained by
the significant increase in the number of cardiopathies of
undetermined cause or other cause than the etiologies reco-
gnized in the “preserved ejection fraction” group (table 2).
In addition, it is possible that the progressive generalization
of the use of Brain Natriuretic Peptide (BNP) [8,9] allows a
positive diagnosis of heart failure whereas the determination
of underlying cardiopathy is unequivocal. We therefore note
that the proportion of diagnosed HF-PSF has increased in ten
years and now represents a majority of cases compared to
HF-ISF with the same diagnostic criteria. The prevalence of
HF-PSF is evaluated differently in the literature depending
on the cut-off values: in the meta-analysis of Vasan [10], its
proportion ranged between 13% to 75% and more recently
the figures converge at around 50% [11,12,13,14]. The
increase, after discharge from hospital, in the prescription of
inhibitors of the renin-angiotensin system and beta-blockers
confirms their efficacy [15] since post-hospital mortality was
reduced in our study. On the other hand, in ten years, we
noted a 25% increase in the number of hospital readmissions:
These hospital readmissions which statistically involved more
patients with HF-ISF, are possibly due to the reduction in
mortality which mechanically increases the number of
remaining patients with heart failure or a trend for the
ageing of this population. In our study, the mean length of
hospital stay was shortened by almost 30% in 10 years from
14 to 10 days. The rate of complications of about 40% inclu-
ding hospital mortality (8%) was identical showing that this
disorder remains serious [16]. Our study confirms that the
total mortality fell, probably because of the wider prescrip-
tion of beta-blockers and inhibitors of the renin-angiotensin
system, and this fall was significant in HF-ISF patients so
that, currently, the mortality is the same whatever the ejec-
tion fraction as in the most recent studies [14,17].
Conclusion
This single-center study conducted at an interval of ten years
clarifies the changes in epidemiological data for hospitalized
HF patients: although age remained statistically stable, a
male prevalence appeared. HF-PSF patients are now in the
majority. LOS was shorter by 30% but hospital mortality
remained the same at around 8%, so that heart failure is still
a serious disorder. Although the mortality at 30 months and
total mortality fell (by 50 and 30% respectively) thanks partly
to an increase in the prescription of inhibitors of the renin-
angiotensin system and beta-blockers, the hospital readmis-
sion rate increased by 25% especially in patients with a lowe-
red ejection fraction, which should lead to the development
of other approaches such as therapeutic patient education
Table 5 Post-discharge outcome (Excluding patients lost to follow-up and hospital deaths).
2002-2004 1992-1994 p
Number of patients n = 284 n = 266
Mean follow-up (months) 30 ± 16 30 ± 17 ns
Post-hospital deaths % (n) 16.5 (47) 30 (80) < 0.001
Hospital readmissions % (n) 38 (108) 28.6 (76) < 0.05
With HF-PSF % (n) 34.6 (55) 26.3 (31) ns
With HF-ISF % (n) 42.7 (53) 30.4 (45) < 0.05
Table 6 Changes in total mortality (Hospital and posthospital) according to ejection fraction.
2002-2004 1992-1994 p
All patients % (n/N) 24.5 (77/314) 35.6 (103/289) < 0.01
With HF-PSF % (n/N) 22 (39/176) 28.5 (37/130) ns
With HF-ISF % (n/N) 27.5 (38/138) 41.5 (66/159) < 0.05
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[18]. The proportion of patients with ischemic and hyperten-
sive heart disease fell with an increase in other etiologies
confirming the improved care for coronary heart disease and
high blood pressure. The total mortality is currently identical
in HF patients whatever the ejection fraction. Neurohormo-
nal activation which has been used increasingly over the last
ten years, has only improved only the vital prognosis in HF-
ISF. A more specific therapy for HF-PSF must therefore be
defined as the total mortality in this condition has remained
stable during this same decade. 
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